Lower urinary tract symptoms: What are the implications for the patients?

被引:51
作者
Scarpa, RM [1 ]
机构
[1] Univ Turin, Osped S Luigi Gonzaga, I-10043 Orbassano, Italy
关键词
BPH; LUTS; bother; quality of life; sexuality; disease management; Europe; Italy; UK;
D O I
10.1159/000049890
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) complain about symptoms such as weak stream, dribbling, intermittency, frequency, nocturia and urgency. To effectively manage these symptoms, it is important to better understand the epidemiology and/or the bothersomeness of these symptoms, the impact of the symptoms on the patient's quality of life and life style, when and why patients seek medical advice and the subsequent management of LUTS/BPH in clinical practice. This paper gives an overview of these issues considering 3 recently conducted European surveys. Although voiding symptoms are more frequent in patients with LUTS/BPH, storage symptoms, such as frequency, urgency, nocturia and urge incontinence, seem to be more bothersome to the patients. LUTS seem to have a negative impact on the patient's quality of life and sexuality and to interfere strongly with daily life activities. With, regard to sexuality, interference with the patient's overall sex life and erection problems is experienced as much more bothersome than ejaculation problems. After the initial symptoms, most patients postpone a visit to the physician and try to adjust their life style to self manage their symptoms. Eventually they seek medical advice because they are too much bothered by their LUTS. In Italy, medical therapy is the most frequently administered treatment option by urologists (57% of patients) followed by surgery (37% of patients). alpha(1)-Adrenoceptor antagonists are the predominant medical therapy prescribed (70% of all medically treated patients), particularly tamsulosin (35% of all medically treated patients). An interview with European urologists confirms that alpha(1)-adrenoceptor antagonists, especially newer uro-selective ones like tamsulosin, are a very appropriate initial treatment choice in the management of both voiding and storage LUTS. Copyright (C) 2001 S. Karger AG,Basel.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 29 条
[1]  
Abrams P, 1997, NEUROUROL URODYNAM, V16, P79
[2]   The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk [J].
Anderson, JB ;
Roehrborn, CG ;
Schalken, JA ;
Emberton, M .
EUROPEAN UROLOGY, 2001, 39 (04) :390-398
[3]   Lower urinary tract symptoms (LUTS): Initial choices and final outcomes Proceedings of a Satellite Symposium held at the XVIth Congress of the European Association of Urology - Geneva, April 7, 2001 - Introduction [J].
Artibani, W .
EUROPEAN UROLOGY, 2001, 40 :1-4
[4]   THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
FOWLER, FJ ;
OLEARY, MP ;
BRUSKEWITZ, RC ;
HOLTGREWE, HL ;
MEBUST, WK ;
COCKETT, ATK ;
BLAIVAS, JG ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557
[5]   Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials [J].
Boyle, P ;
Gould, AL ;
Roehrborn, CG .
UROLOGY, 1996, 48 (03) :398-405
[6]   Introduction and concluding remarks [J].
Chapple, CR .
EUROPEAN UROLOGY, 1999, 36 :1-6
[7]  
Chapple CR, 1998, BRIT J UROL, V81, P34
[8]   α1-blockers for BPH:: Are there differences? [J].
de Mey, C .
EUROPEAN UROLOGY, 1999, 36 :52-63
[9]   Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia [J].
Debruyne, FMJ ;
Jardin, A ;
Colloi, D ;
Resel, L ;
Witjes, WPJ ;
Delauche-Cavallier, MC ;
McCarthy, C ;
Geffriaud-Ricouard, C .
EUROPEAN UROLOGY, 1998, 34 (03) :169-175
[10]   A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction [J].
Djavan, B ;
Marberger, M .
EUROPEAN UROLOGY, 1999, 36 (01) :1-12